Cmv glycoproteins and recombinant vectors
AssigneeOregon Health & Science University
InventorsLouis Picker, Klaus Frueh, Scott G. Hansen, Collin Powers
Life of this patent
Estimating the term…
Abstract
This invention also relates to recombinant vectors expressing one or more of the human CMV (HCMV) glycoproteins US2, US3, US6 and US11 or corresponding functional rhesus CMV (RhCMV) homologues Rh182, Rh184, Rh185 or Rh189, methods of making them, uses for them, expression products from them, and uses for the expression products. This invention also relates to recombinant cytomegalovirus vectors vectors lacking one or more of the glycoproteins, methods of making them, uses for them, expression products from them, and uses for the expression products.
Claims3
A method of determining efficacy of a CMV vaccine, comprising (a) administering a CMV vaccine to a test subject, (b) challenging the test subject with a CMV vector, wherein the glycoproteins within the US2 to US11 region of CMV are deleted from the CMV vector, and wherein the CMV vector contains and expresses at least one immunogen of the CMV vaccine, and (c) measuring a CD8+ T cell response, wherein the CMV vaccine in efficacious if a CD8+ T cell response is protective against the challenge with the CMV vector lacking the glycoproteins within the US2 to US11 region of CMV and wherein the CMV vector contains and expresses at least one immunogen of the CMV vaccine.
Dependencies are inferred from the claim text.